Adoption of Pharmacogenomic Testing: A Marketing Perspective.

Publisher: Frontiers Media] Country of Publication: Switzerland NLM ID: 101548923 Publication Model: eCollection Cited Medium: Print ISSN: 1663-9812 (Print) Linking ISSN: 16639812 NLM ISO Abbreviation: Front Pharmacol Subsets: PubMed not MEDLINE

Original Publication: [Lausanne : Frontiers Media]

Pharmacogenomics is becoming an important part of clinical practice and it is considered one of the basic pillars of personalised medicine. However, the rate of pharmacogenomics adoption is still low in many healthcare systems, especially in low- or middle-income countries. The low level of awareness of healthcare specialists could be a potential reason due to which pharmacogenomics application is still in a premature stage but there are several other barriers that impede the aforementioned process, including the lack of the proper promotion of pharmacogenomic testing among interested stakeholders, such as healthcare professionals and biomedical scientists. In this study, we outline the available marketing theories and innovation that are applied to personalized medicine interventions that would catalyze the adoption of pharmacogenomic testing services in clinical practice. We also present the current ethical and legal framework about genomic data and propose ways to tackle the main concerns mentioned in the literature and to improve the marketing perspective of PGx.
Competing Interests: Authors KK and CM were employed by the company The Golden Helix Foundation. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2021 Koufaki, Karamperis, Vitsa, Vasileiou, Patrinos and Mitropoulou.)

BMC Med Genomics. 2018 Oct 26;11(1):94. (PMID: 30367635)
BMJ Open. 2011 Jul 29;1(1):e000110. (PMID: 22021765)
Nat Rev Genet. 2011 Dec 13;13(2):146; author reply 146. (PMID: 22158309)
Pharmgenomics Pers Med. 2017 Dec 05;10:279-285. (PMID: 29255371)
Ghana Med J. 2015 Mar;49(1):50-6. (PMID: 26339085)
Pharmgenomics Pers Med. 2019 Oct 07;12:247-255. (PMID: 31632127)
Per Med. 2020 Jul 1;17(4):251-260. (PMID: 32589096)
JMIR Mhealth Uhealth. 2020 Jul 6;8(7):e18072. (PMID: 32442132)
JCO Oncol Pract. 2020 Dec;16(12):799-800. (PMID: 33301699)
Clin Pharmacol Ther. 2018 May;103(5):752-755. (PMID: 29417560)
BMC Med Genomics. 2018 Feb 13;11(1):18. (PMID: 29433521)
Am J Pharm Educ. 2010 Feb 10;74(1):7. (PMID: 20221358)
Clin Genet. 2012 Oct;82(4):388-94. (PMID: 22698141)
Pharmacogenomics. 2016 Apr;17(5):455-8. (PMID: 27027537)
Per Med. 2014 Jan;11(1):15-26. (PMID: 29751393)
Pharmacy (Basel). 2017 Jun 30;5(3):. (PMID: 28970448)
J Pers Med. 2020 Sep 18;10(3):. (PMID: 32962013)
Clin Pharmacol Ther. 2017 Nov;102(5):739-741. (PMID: 28581028)
J Pers Med. 2020 Oct 24;10(4):. (PMID: 33114420)
Risk Manag Healthc Policy. 2020 Aug 21;13:1279-1291. (PMID: 32904476)
Pharmacogenet Genomics. 2020 Jun;30(4):73-80. (PMID: 32187156)
J Neural Transm (Vienna). 2017 Jan;124(1):25-32. (PMID: 26645377)
Am J Hum Genet. 2020 Oct 1;107(4):589-595. (PMID: 33007198)
Cell Tissue Bank. 2011 May;12(2):71-80. (PMID: 20012777)
J Pharm Sci. 2017 Sep;106(9):2368-2379. (PMID: 28619604)
EMBO Rep. 2014 May;15(5):472-6. (PMID: 24723683)
J Eval Clin Pract. 2015 Aug;21(4):703-9. (PMID: 25929423)

Keywords: awareness; genetic testing services; innovation; marketing strategies; patients; personalized medicine; pharmacogenomics

Date Created: 20211004 Latest Revision: 20211005

20231215

PMC8484788

10.3389/fphar.2021.724311

34603034